Diabetes · DPP-4 InhibitorRegulatory Approvalcompetitivemid-term

Ajanta Pharma submits ANDA for Sitagliptin and Metformin Hydrochloride

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/15/2026, 6:31:55 AM

Assessment confidence: 72% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Ajanta Pharma's submission of an ANDA for Sitagliptin and Metformin Hydrochloride signals increased competition in the diabetes treatment market. This could impact pricing and market share for existing therapies, necessitating strategic adjustments by other players in the space. Regulatory context from FDA (FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)) supports the near-term read. Assessment grounded in 21 ranked evidence items (11 high-relevance).

Strategic Assessment

Portfolio teams should assess the potential impact on market share and pricing strategies for existing diabetes therapies. The strongest clinical anchor is A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) (ClinicalTrials.gov), sponsor/company relevance (merck). In Diabetes · DPP-4 Inhibitor, 8 regulatory and 1 competitive items passed relevance filtering for Ajanta Pharma.

Competitive Pressure

The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). This submission could increase competition in the diabetes treatment market, particularly against established DPP-4 inhibitors.

Regulatory Outlook

Regulatory risk is concentrated around FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG) (FDA). Entity match (ajanta pharma); Regulatory pathway relevance (nda). The ANDA submission indicates a regulatory pathway that could lead to increased market access for Ajanta Pharma, impacting the competitive landscape and necessitating compliance monitoring.

Key Risks

Elevated medium regulatory exposure for Ajanta Pharma could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The introduction of a new competitor could pressure pricing and market share for established DPP-4 inhibitors, potentially affecting revenue streams for current market leaders.
Upside for Ajanta Pharma may improve if Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata (ClinicalTrials.gov) delivers favorable follow-through.
CDK4/6 inhibitors (CDK4/6i) represent the standard treatment for HR+/HER2- ABC. The study assessed the efficacy and safety profiles of CDK4/6i from first-line (1 L) to third-line (3 L) in patients with HR+/HER2- ABC from high-altitude versus low-altitude regions.
Upside for Ajanta Pharma may improve if An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Ajanta Pharma may improve if A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor the review progress and potential approval timeline for ANDA216516.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (ajanta pharma); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (sitagliptin); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — METFORMIN HYDROCHLORIDE AND SITAGLIPTIN PHOSPHATE (ORIG)
FDAhigh relevance
Entity match (sitagliptin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (sitagliptin); Regulatory pathway relevance (nda)
FDA document
View source
FDA TA — SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (ORIG)
FDAhigh relevance
Entity match (sitagliptin); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (metformin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (metformin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — METFORMIN HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Entity match (metformin hydrochloride); Regulatory pathway relevance (nda)
FDA document
View source

A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With CDK4/6 Inhibitor and an Aromata
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Novartis)
FDA document
View source
A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Mild Hepatic Impairment, Moderate Hepatic Impairment, and No
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Partial Enteral Nutrition as Therapeutic Augmentation of Advanced Pharmacological Therapy in Patients With Active Crohn's Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)

Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Discovery of azaindole/indole-fused pyrimidine tetracyclic scaffolds as novel potent CDK7 inhibitors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Preclinical characterization of HEC116094, an oral inhibitor of the influenza A virus polymerase PB2 subunit.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Recent advances in functional studies of coronavirus NSP13 helicase and challenges in inhibitor development.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Ajanta Pharma
Sitagliptin
Metformin Hydrochloride

Commercial impact

medium

The introduction of a new competitor could pressure pricing and market share for established DPP-4 inhibitors, potentially affecting revenue streams for current market leaders.

Regulatory impact

medium

The ANDA submission indicates a regulatory pathway that could lead to increased market access for Ajanta Pharma, impacting the competitive landscape and necessitating compliance monitoring.

What to watch

Monitor the review progress and potential approval timeline for ANDA216516.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.